The first-in-class XPO1 inhibitor selinexor downregulated surface HLA-E expression on all CLL samples tested and led to enhanced NK cell lysis of CLL cells and IFNγ production. This evidence concerns the gene XPO1 and B-cell chronic lymphocytic leukemia.